Vesugen (20 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. Titrate slowly to assess tolerance; many protocols stabilize at the 1 to 1.5 mg range.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 6.67 mg/mL, 1 unit = 0.01 mL » 66.7 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12+ months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F); avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 12 week daily protocol with gradual titration.

Peptide Vials (Vesugen, 20 mg each):

• 8 weeks: ~2 vials (~30 mg used).
• 12 weeks: ~3 vials (~50 mg used).

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56 syringes. 12 weeks: 84 syringes.

Bacteriostatic Water (10 mL bottles):

• Use 3.0 mL per vial.
• 8 weeks: 1 x 10 mL bottle. 12 weeks: 1 x 10 mL bottle.

Alcohol Swabs:

• 8 weeks: 112 swabs (2 x 100-count boxes).
• 12 weeks: 168 swabs (2 x 100-count boxes).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.

How This Works

Vesugen belongs to a class of ultrashort peptide bioregulators studied by Khavinson and colleagues. These tripeptides are proposed to enter cells and bind regulatory regions of DNA, modulating gene expression at nanomolar concentrations. Preclinical research suggests Vesugen upregulates Ki-67 (a proliferation marker) in vascular endothelium and supports the expression of genes involved in vascular homeostasis and angiogenesis. Human clinical data remain limited; most evidence is from in vitro and rodent studies.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Preclinical models suggest support for vascular endothelial proliferation and function.
• May modulate aging-related gene expression markers in vascular tissue.
• Ultrashort peptides of this class generally exhibit favorable tolerability profiles in preclinical work.
• Human safety and efficacy data remain limited; mild injection-site reactions (redness, itch) may occur.

Lifestyle Factors

Complementary strategies for best outcomes.

• Support cardiovascular health with regular aerobic exercise.
• Maintain a nutrient-dense diet emphasizing omega-3 fatty acids and antioxidants.
• Prioritize quality sleep and stress management to support vascular function.
• Avoid smoking and excessive alcohol consumption.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Khavinson VK. Peptides and Ageing (review of bioregulatory peptide mechanisms).
2. Khavinson VK et al. Peptide regulation of gene expression: systematic review.